Management of hyperinsulinism in infancy and childhood.
Hyperinsulinism (HI) in infancy presents a formidable challenge for the paediatrician as it is one of the most difficult problems to manage in contemporary paediatric endocrinology. Although there have been major advances in understanding the condition over the last five years, the neurological outcome remains poor choice, and the choice of treatments continue to be unsatisfactory. This review article updates the management of HI derived from a Consensus Workshop held by the European Network for Research into Hyperinsulinism (ENRHI) in 1999.
Hussain
K
K
London Centre for Paediatric Endocrinology and Metabolism, Great Ormond Street Hospital for Children NHS Trust, and the Institute of Child Health, University College London, UK.
Aynsley-Green
A
A
D001786:Blood Glucose / Q000378:metabolism; D002121:Calcium Channel Blockers / Q000627:therapeutic use; D002648:Child; D002675:Child, Preschool; D002740:Chlorothiazide / Q000627:therapeutic use; D003981:Diazoxide / Q000627:therapeutic use; D005934:Glucagon / Q000627:therapeutic use; D006801:Humans; D006946:Hyperinsulinism / Q000175:diagnosis / Q000209:etiology / Q000628:therapy*; D007223:Infant; D007328:Insulin / Q000378:metabolism; D000078790:Insulin Secretion; D007515:Islets of Langerhans / Q000378:metabolism; D015282:Octreotide / Q000627:therapeutic use; D010180:Pancreatectomy
D001786:Blood Glucose; D002121:Calcium Channel Blockers; D007328:Insulin; D002740:Chlorothiazide; D005934:Glucagon; D003981:Diazoxide; D015282:Octreotide